Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Option Care Health Q4 2025 Earnings Call - Reaffirmed 2026 Guidance While Managing a Material Stelara Biosimilar Headwind
Option Care Health closed 2025 with revenue of $5.6 billion, adjusted EBITDA of $471 million and adjusted EPS of $1.72, results in line with the January pre-release. Management is selling a clear narr...
- 2025 top-line and operating results were in line with the January pre-announcement: net revenue $5.6 billion, up 13% year over year.
- Adjusted EBITDA for 2025 was $471 million, a 6% increase, with an EBITDA margin of 8.3%.
- Adjusted diluted EPS grew 9% to $1.72, helped by share repurchases exceeding $300 million in 2025 and an expanded $500 million repurchase authorization.
- +12 more takeaways
American Tower Fourth Quarter 2025 Earnings Call - DISH Default Forces Conservative 2026 Guide, Upside If Recovered
American Tower closed 2025 with solid execution and an 8% increase in attributable AFFO per share as adjusted, paced by a robust fourth quarter where AFFO rose north of 13%. The company leaned into it...
- 2025 results: attributable AFFO per share as adjusted grew ~8% for the year, with over 13% growth in Q4, driven by strong leasing and CoreSite performance.
- DISH default: DISH failed to meet payment obligations; management removed 100% of DISH revenue from run‑rate and guidance. DISH represented ~4% of U.S. and Canada property revenue, about $200 million per year, with contract exposure into 2035–2036.
- Guidance posture: 2026 Organic Tenant Billings Growth guide is ~1% consolidated, or ~4% ex‑DISH churn. U.S. and Canada guide is ~0.5%, or ~4.5% excluding DISH.
- +9 more takeaways
Albany International Corp Q4 2025 Earnings Call - Engineered Composites Surge Offsets Machine Clothing Weakness, Salt Lake Site Under Strategic Review
Albany closed Q4 with a clear bifurcation: Engineered Composites ramped sharply and carried the quarter, while Machine Clothing continued to feel pressure from China and a January equipment failure th...
- Consolidated Q4 revenue $321.2 million, up 12% year-over-year; Adjusted EBITDA $57.3 million, or 17.8% of sales.
- Engineered Composites drove the quarter: revenue $143.7 million versus $98.8 million a year ago, with broad-based program ramps.
- Machine Clothing revenue fell to $177.5 million from $188.1 million year-over-year, a mid-single-digit decline led by softness in China.
- +12 more takeaways
Xometry Q4 2025 Earnings Call - Record growth and margin expansion as AI-native marketplace scales (CEO handoff announced)
Xometry closed 2025 with a clean acceleration: record Q4 and full-year revenue, sequentially improving profitability, and clear evidence that its AI-native marketplace is producing both top-line growt...
- Q4 2025 revenue $192+ million, up 30% year-over-year, with a 200 basis point sequential acceleration from Q3.
- Marketplace revenue in Q4 was $178 million, up 33% year-over-year; supplier services revenue was $13.9 million.
- Q4 marketplace gross margin expanded to 35.3%, up 80 basis points year-over-year; overall Q4 gross margin was 39.1% (gross profit $75.2 million).
- +14 more takeaways
Repligen Corporation Q4 2025 Earnings Call - Returned to robust growth, guiding cautiously into 2026 with margin expansion and M&A optionality
Repligen closed 2025 with a strong finish, reporting Q4 revenue of $198 million (14% organic growth) and full-year revenue of $738 million. Management said the company outperformed October guidance, d...
- Q4 revenue $198 million, up 18% reported and 14% organic; full-year revenue $738 million, up 16% reported and organic non-COVID, 14% organic.
- Repligen beat the high end of its October guidance for both revenue and adjusted operating income, citing broad portfolio momentum and stronger order trends into Q4.
- Proteins and analytics were the engines of growth, proteins up >30% in Q4 and 31% for the year, analytics >30% in Q4 and 37% for the year (21% excluding M&A).
- +14 more takeaways
Establishment Labs Q4 2025 Earnings Call - US Motiva Momentum Drives Profitability and 2026 Guidance $264–266M
Establishment Labs closed 2025 with a fast-growing U.S. rollout that pushed revenue to $211.1 million, up 27.2% year over year, and carved out a path to sustained profitability. Q4 revenue was $64.6 m...
- Q4 2025 revenue was $64.6 million, up 45.2% versus Q4 2024, driving full-year 2025 revenue of $211.1 million, up 27.2% year over year.
- U.S. Motiva revenue for 2025 totaled $45.6 million, with Q4 U.S. Motiva sales of $17.3 million, a faster adoption curve than investors expected.
- Gross profit in Q4 was $45.5 million, or 70.5% of revenue, marking a 200 basis point improvement year over year and a 330 basis point improvement for all of 2025 versus 2024.
- +13 more takeaways
Ziff Davis Q4 and FY2025 Earnings Call - Search-driven Affiliate Hit Keeps Tech & Shopping in the Doghouse
Ziff Davis posted modest full-year growth while a search-driven collapse in affiliate commerce carved into Q4 results. FY2025 revenue rose 3.5% to $1.45 billion and adjusted EBITDA edged up to $495.1 ...
- Full year 2025 revenue rose 3.5% to $1,451.3 million, and adjusted EBITDA increased to $495.1 million, with an FY adjusted EBITDA margin of 34.1%.
- Q4 2025 revenue was $406.7 million, down 1.5% year-over-year, and Q4 adjusted EBITDA fell 5% to $163.2 million, with a Q4 adjusted EBITDA margin of 40.1%.
- Tech and Shopping was the clear drag, down 18% in Q4, driven primarily by a decline in web search traffic that materially reduced affiliate commerce commissions.
- +14 more takeaways
Arvinas Q4 2025 Earnings Call - Company pivots to four Phase I programs, eyes multiple 2026 data readouts
Arvinas used its Q4 2025 results call to signal a clear strategic reset: the company is now a predominantly Phase I clinical-stage biotech, concentrating resources on four clinical programs while keep...
- Arvinas is repositioned as a Phase I-focused company, concentrating on four clinical programs: ARV-102 (LRRK2), ARV-806 (KRAS G12D), ARV-393 (BCL6) and ARV-027 (polyQ AR for SBMA).
- Management expects multiple meaningful data readouts and clinical advancements across 2026 that will determine program prioritization and value creation.
- ARV-102 (LRRK2 degrader) achieved brain penetration and showed greater than 50% LRRK2 reduction in CSF in earlier studies; patient biomarker data will be presented at the AD/PD conference and a Phase 1b in PSP is planned for H1 2026.
- +11 more takeaways
Scotiabank Q1 2026 Earnings Call - ROE Ahead of Plan as Credit Costs Stay Elevated
Scotiabank posted a strong start to fiscal 2026, delivering adjusted earnings of CAD 2.7 billion and EPS of CAD 2.05, with return on equity at 13% and CET1 at 13.3% after buybacks. Management says the...
- Adjusted net income CAD 2.7 billion, diluted EPS CAD 2.05, up 16% year-over-year, driven by revenue growth and expense control.
- Return on equity 13.0%, up 120 basis points year-over-year, management says ROE is tracking ahead of Investor Day expectations and they have increased confidence in hitting a 14%+ medium-term target.
- CET1 ratio 13.3% after repurchasing 4.9 million shares in Q1 under the NCIB; total buybacks to date were about 15.7 million shares, and management expects to renew the NCIB in May.
- +12 more takeaways
Brightstar Lottery Q4 2025 and FY2025 Earnings Call - Italy Lotto License Recasts Growth, €1.43B Final Installment Hits in Q2 2026
Brightstar completed a strategic transformation in 2025, exiting non-lottery gaming and emerging as a pure-play global lottery operator with stronger leverage metrics, a bigger shareholder-return prog...
- Brightstar completed a portfolio reshape in 2025, divesting the IGT gaming business and positioning itself as a focused, pure-play lottery operator. That strategic tidy-up underpins the company narrative on valuation and capital allocation going forward.
- Brightstar secured the Italy Lotto license for nine years, creating a platform to scale iLottery, iCasino, and sports betting across a retail footprint of over 50,000 points of sale. Management sees Italy as a core multi-year growth engine.
- The Italy license carries large upfront fees. Two installments were paid in 2025 and the final installment is EUR 1.43 billion (Brightstar’s share EUR 880 million, roughly $1 billion), expected to be paid in Q2 2026. That payment will materially affect reported cash from operations and leverage in the short term.
- +12 more takeaways